1-6 of 6
Melanie Valenti
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Circulating microRNA Analysis in a Prospective Co-clinical Trial Identifies MIR652–3p as a Response Biomarker and Driver of Regorafenib Resistance Mechanisms in Colorectal Cancer

Somaieh Hedayat, Luciano Cascione, David Cunningham, Marta Schirripa, Andrea Lampis, Jens C. Hahne, Nina Tunariu, Sung Pil Hong, Silvia Marchetti, Khurum Khan, Elisa Fontana, Valentina Angerilli, Mia Delrieux, Daniel Nava Rodrigues, Letizia Procaccio, Sheela Rao, David Watkins, Naureen Starling, Ian Chau, Chiara Braconi, Nicos Fotiadis, Ruwaida Begum, Naomy Guppy, Louise Howell, Melanie Valenti, Scott Cribbes, Bernadett Kolozsvari, Vladimir Kirkin, Sara Lonardi, Michele Ghidini, Rodolfo Passalacqua, Raghad Elghadi, Luca Magnani, David J. Pinato, Federica Di Maggio, Filippo Ghelardi, Elisa Sottotetti, Guglielmo Vetere, Paolo Ciracì, Georgios Vlachogiannis, Filippo Pietrantonio, Chiara Cremolini, Alessio Cortellini, Fotios Loupakis, Matteo Fassan, Nicola Valeri
Journal: Clinical Cancer Research
Clin Cancer Res (2024) 30 (10): 2140–2159.
https://doi.org/10.1158/1078-0432.CCR-23-2748
Published: 15 May 2024
View articletitled, Circulating microRNA Analysis in a Prospective Co-clinical Trial Identifies MIR652–3p as a Response Biomarker and Driver of Regorafenib Resistance Mechanisms in Colorectal Cancer
Open the PDF for Circulating microRNA Analysis in a Prospective Co-clinical Trial Identifies MIR652–3p as a Response Biomarker and Driver of Regorafenib Resistance Mechanisms in Colorectal Cancer in another window
Includes: Multimedia, Supplementary data
Journal Articles

Dual Blockade of the PI3K/AKT/mTOR (AZD8055) and RAS/MEK/ERK (AZD6244) Pathways Synergistically Inhibits Rhabdomyosarcoma Cell Growth In Vitro and In Vivo

Jane Renshaw, Kathryn R. Taylor, Ryan Bishop, Melanie Valenti, Alexis De Haven Brandon, Sharon Gowan, Suzanne A. Eccles, Ruth R. Ruddle, Louise D. Johnson, Florence I. Raynaud, Joanna L. Selfe, Khin Thway, Torsten Pietsch, Andrew D. Pearson, Janet Shipley
Journal: Clinical Cancer Research
Clin Cancer Res (2013) 19 (21): 5940–5951.
https://doi.org/10.1158/1078-0432.CCR-13-0850
Published: 31 October 2013
View articletitled, Dual Blockade of the PI3K/AKT/mTOR (AZD8055) and RAS/MEK/ERK (AZD6244) Pathways Synergistically Inhibits Rhabdomyosarcoma Cell Growth In Vitro and In Vivo
Open the PDF for Dual Blockade of the PI3K/AKT/mTOR (AZD8055) and RAS/MEK/ERK (AZD6244) Pathways Synergistically Inhibits Rhabdomyosarcoma Cell Growth In Vitro and In Vivo in another window
Includes: Supplementary data
Journal Articles

In vitro and In vivo Pharmacokinetic-Pharmacodynamic Relationships for the Trisubstituted Aminopurine Cyclin-Dependent Kinase Inhibitors Olomoucine, Bohemine and CYC202

Florence I. Raynaud, Steven R. Whittaker, Peter M. Fischer, Steven McClue, Michael I. Walton, S. Elaine Barrie, Michelle D. Garrett, Paul Rogers, Simon J. Clarke, Lloyd R. Kelland, Melanie Valenti, Lisa Brunton, Suzanne Eccles, David P. Lane, Paul Workman
Journal: Clinical Cancer Research
Clin Cancer Res (2005) 11 (13): 4875–4887.
https://doi.org/10.1158/1078-0432.CCR-04-2264
Published: 01 July 2005
View articletitled, In vitro and In vivo Pharmacokinetic-Pharmacodynamic Relationships for the Trisubstituted Aminopurine Cyclin-Dependent Kinase Inhibitors Olomoucine, Bohemine and CYC202
Open the PDF for In vitro and In vivo Pharmacokinetic-Pharmacodynamic Relationships for the Trisubstituted Aminopurine Cyclin-Dependent Kinase Inhibitors Olomoucine, Bohemine and CYC202 in another window
Journal Articles

Preclinical Antitumor Activity and Pharmacodynamic Studies with the Farnesyl Protein Transferase Inhibitor R115777 in Human Breast Cancer

Lloyd R. Kelland, Vicki Smith, Melanie Valenti, Lisa Patterson, Paul A. Clarke, Simone Detre, Dave End, Angela J. Howes, Mitch Dowsett, Paul Workman, Stephen R. D. Johnston
Journal: Clinical Cancer Research
Clin Cancer Res (2001) 7 (11): 3544–3550.
Published: 01 November 2001
View articletitled, Preclinical Antitumor Activity and Pharmacodynamic Studies with the Farnesyl Protein Transferase Inhibitor R115777 in Human Breast Cancer
Open the PDF for Preclinical Antitumor Activity and Pharmacodynamic Studies with the Farnesyl Protein Transferase Inhibitor R115777 in Human Breast Cancer in another window
Journal Articles

Pharmacokinetic/Pharmacodynamic Study of ZD9331, a Nonpolyglutamatable Inhibitor of Thymidylate Synthase, in a Murine Model Following Two Curative Administration Schedules

G. Wynne Aherne, Anthea Hardcastle, Emma Ward, Donna Dobinson, Thomas Crompton, Melanie Valenti, Lisa Brunton, Ann L. Jackman
Journal: Clinical Cancer Research
Clin Cancer Res (2001) 7 (9): 2923–2930.
Published: 01 September 2001
View articletitled, Pharmacokinetic/Pharmacodynamic Study of ZD9331, a Nonpolyglutamatable Inhibitor of Thymidylate Synthase, in a Murine Model Following Two Curative Administration Schedules
Open the PDF for Pharmacokinetic/Pharmacodynamic Study of ZD9331, a Nonpolyglutamatable Inhibitor of Thymidylate Synthase, in a Murine Model Following Two Curative Administration Schedules in another window
Journal Articles

Comparison of Thymidylate Synthase (TS) Protein Up-Regulation after Exposure to TS Inhibitors in Normal and Tumor Cell Lines and Tissues

Sarah J. Welsh, Jenny Titley, Lisa Brunton, Melanie Valenti, Paul Monaghan, Ann L. Jackman, G. Wynne Aherne
Journal: Clinical Cancer Research
Clin Cancer Res (2000) 6 (6): 2538–2546.
Published: 01 June 2000
View articletitled, Comparison of Thymidylate Synthase (TS) Protein Up-Regulation after Exposure to TS Inhibitors in Normal and Tumor Cell Lines and Tissues
Open the PDF for Comparison of Thymidylate Synthase (TS) Protein Up-Regulation after Exposure to TS Inhibitors in Normal and Tumor Cell Lines and Tissues in another window